Published in Blood Weekly, July 12th, 2001
"Although the use of drugs which damage stem cells is common in patients with Hodgkin's disease (HD), factors affecting peripheral blood progenitor cell (PBPC) mobilization have not been clearly established in this group of patients," according to Dr. Miguel A. Canales and colleagues at Madrid's La Paz University Hospital.
Canales and coworkers found that multiple cycles of the mini-BEAM chemotherapy regimen,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.